Evidence map›Paper›PMID 27582896›Full record

ReviewTherapeutic advances in neurological disorders2016

Eletriptan in the management of acute migraine: an update on the evidence for efficacy, safety, and consistent response.

Matilde Capi, Martina Curto, Luana Lionetto, Fernando de Andrés, Giovanna Gentile, Andrea Negro, Paolo Martelletti

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Therapeutic advances in neurological disorders, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 38 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 2 countries.

Matilde CapiNESMOS Department, Sapienza University of Rome, Italy.
Martina CurtoSapienza University of Rome, Azienda Ospedaliera Sant'Andrea Via di Grottarossa 1035-1039, Rome 00189, Italy.
Luana LionettoAdvanced Molecular Diagnostics, IDI-IRCCS, Rome, Italy.
Fernando de AndrésCICAB Clinical Research Centre, Extremadura University Hospital and Medical School, Badajoz, Spain.
Giovanna GentileNESMOS Department, Sapienza University of Rome, Italy Psychiatry and Neurology Department, Sapienza University of Rome, Italy Department of Psychiatry, Harvard Medical School, Boston, MA, USA Department of Molecular Medicine, Sant'Andrea Medical Center, Sapienza University of Rome, Italy Regional Referral Headache Center, Sant'Andrea Hospital, Rome, Italy Advanced Molecular Diagnostics, IDI-IRCCS, Rome, Italy.
Andrea NegroDepartment of Molecular Medicine, Sant'Andrea Medical Center, Sapienza University of Rome, Italy Regional Referral Headache Center, Sant'Andrea Hospital, Rome, Italy.
Paolo MartellettiDepartment of Molecular Medicine, Sant'Andrea Medical Center, Sapienza University of Rome, Italy Regional Referral Headache Center, Sant'Andrea Hospital, Rome, Italy.
CTO Andrea Alesini · ITSapienza University of Rome · ITAzienda Ospedaliera Sant'Andrea · ITIstituti di Ricovero e Cura a Carattere Scientifico · ITUniversidad de Extremadura · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Migraine is a multifactorial, neurological and disabling disorder, also characterized by several autonomic symptoms. Triptans, selective serotonin 5-HT1B/1D agonists, are the first-line treatment option for moderate-to-severe headache attacks. In this paper, we review the recent data on eletriptan clinical efficacy, safety, and tolerability, and potential clinically relevant interactions with other drugs. Among triptans, eletriptan shows a consistent and significant clinical efficacy and a good tolerability profile in the treatment of migraine, especially for patients with cardiovascular risk factors without coronary artery disease. It shows the most favorable clinical response, together with sumatriptan injections, zolmitriptan and rizatriptan. Additionally, eletriptan shows the most complex pharmacokinetic/dynamic profile compared with the other triptans. It is metabolized primarily by the CYP3A4 hepatic enzyme and therefore the concomitant administration of CYP3A4-potent inhibitors should be carefully evaluated. A relatively low risk of serotonin syndrome is given by the co-administration with serotoninergic drugs. No clinically relevant interaction has been found with drugs used for migraine prophylactic treatment or other acute drugs, with the exception of ergot derivatives that should not be co-administered with eletriptan.

Indexed as

acute migraineefficacyeletriptansafety

Identifiers

PMID27582896
PMCPMC4994780
OpenAlexW2410675934

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.